See related research article by Nannini *et al.*, <http://arthritis-research.com/content/10/5/R124>

It has been brought to our attention that Figure 2b in our recently published paper \[[@B1]\] contains an error. Specifically, we inadvertently entered -6.4 rather than +6.4 for the Nadaskevich paper \[[@B2]\] reported in Figure 2b. Recalculation of the summary estimate for diffusing lung capacity of carbon monoxide (DLCO) in this figure revealed a summary mean difference of 3.74, with 95% confidence interval (0.09 to 7.40). This effect is now statistically significant, although the overall conclusion of our meta-analysis, that cyclophosphamide treatment did not result in clinically significant improvement of pulmonary function, is unchanged by this recalculation, as the improvement remains less than the predefined criterion of 10%. The corrected figure 2b is given here as Figure [1](#F1){ref-type="fig"}.

![**Forest plot of the overall meta-analysis result in the randomized clinical trials**. Comparison of the diffusing capacity for carbon monoxide (DLCO) at 12 months for patients with scleroderma lung disease treated with cyclophosphamide versus a control group. See Table 2 \[[@B1]\] for study details. RCT, randomized clinical trial; SE, standard error; CI, confidence interval; Chi2, chi-squared; df, degree of freedom; I^2^, *I*-squared; Z, Z value; Mean difference, weighted mean difference; Random, random-effects.](ar2679-1){#F1}
